▲ +77.85% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for NextCure in the last 3 months. The average price target is $23.33, with a high forecast of $55.00 and a low forecast of $10.00. The average price target represents a 77.85% upside from the last price of $13.12.
The current consensus among 8 contributing investment analysts is to hold stock in NextCure. This rating has held steady since July 2019, when it changed from a Buy consensus rating.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.